Novo Nordisk


Firma Chun Cheong
Concise Prescribing Info
Adjunct to a reduced-calorie diet & increased physical activity for wt management in adult patients w/ an initial BMI of ≥30 kg/m2 (obese), or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points), & body wt >60 kg.
Dosage/Direction for Use
SC Initially 0.6 mg once daily. Should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval.
May be taken with or without food.
Special Precautions
Do not administer by IV or IM. Risk of developing acute pancreatitis. Higher rate of cholelithiasis & cholecystitis. Reports of thyroid adverse events (eg, goitre), particularly in patients w/ pre-existing thyroid disease. Increase in heart rate. Potential risk of dehydration. Increased risk of hypoglycaemia in patients w/ type 2 DM receiving concomitant insulin &/or sulfonylurea. Reports of episodes of clinically significant hypoglycaemia in adolescents ≥12 yr. Not a substitute for insulin in patients w/ DM. Not recommended in patients w/ CHF NYHA class IV; obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; inflammatory bowel disease & diabetic gastroparesis; severe renal impairment (CrCl <30 mL/min) including ESRD; severe hepatic impairment; elderly ≥75 yr; patients treated w/ other products for wt management. Use w/ caution in patients w/ mild or moderate hepatic impairment. Do not use w/ other GLP-1 receptor agonist in patients w/ type 2 DM. May impair ability to drive & use machines. Do not use during pregnancy & breast-feeding. Safety & efficacy in childn <12 yr has not been established.
Adverse Reactions
Headache; nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, abdominal pain upper, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
Drug Interactions
Clinically relevant interaction w/ active substances w/ poor solubility or narrow therapeutic index eg, warfarin cannot be excluded.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Saxenda soln for inj (pre-filled pen) 6 mg/mL
3 mL x 3 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in